The immunoprotein diagnostic testing is the procedure of diagnosing the concentration of immunoproteins in the body of a living organism. Immunoprotein is a protein, which has immunological abilities providing immunity against pathogenic substances or organisms. These proteins create the integrated body system of cells, tissues, organs, or cell products to neutralize antigens. These proteins also enable the detection of many diseases as they exhibit an abnormal rise in the blood concentration in the diseased state. When exposed to antigen, the levels of these proteins raise ten to hundred folds within one or two days. The application of these immunoproteins has changed their paradigm to rapid testing from microbial testing.
The rise in the need for quick and accurate detection of the diseases coupled with the increasing demand for precautionary healthcare in emerging economies is the major driving force behind the growth in the global immunoprotein diagnostic testing industry. The powerful global network of distributors is another factor fueling the developing market. Apart from this, the technical advancement and the commoditization of products are also expected to drive the market in the coming years.
In contrast to this, the high cost of diagnosis and the deployed base of conventional ELISA test are the main hindrances limiting the growth of the global immunoprotein diagnostic testing industry. However, immunochromatography, research and development, and expansion of the immunoprotein diagnostic testing industry in emerging economies will cater for huge opportunities for the increment in the global immunoprotein diagnostic testing market in near future.
Enzyme-based immunoassay, immunoturbidity assay, immunofluorescence assay, radioimmunoassay, chemiluminescence assay, and immunoprotein electrophoresis are segments of immunoprotein diagnostic testing industry based on the assay technology.
The chemiluminescence assay market is recognized as the fastest developing market segment of the immunoprotein diagnostic testing industry. The sensitivity, simplicity in utilization, and the broad array of application are the reasons behind this development. Contrarily, the radioimmunoassay market is likely to decline as it is being substituted by better and more secure technologies such as chemiluminescence assay, ELISA, immunofluorescence assay, and others.
The restrictions imposed by the governments on the utilization of radioactive substances have significantly affected the growth in the immunoprotein diagnostic testing market. The compliance with regulatory firms, high cost of assay devices and safety equipment have further hampered the growth of the radioimmunoassay market. The immunofluorescence assay and immunoturbidity assay industries will be developing at a moderate CAGR of around 5% during the period of 2013 to 2019.
Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1253
Based on the type of immunoprotein tests, the global immunoprotein diagnostic testing market is classified into haptoglobin diagnostic tests, complement system protein diagnostic tests, free light chain diagnostic tests, C-reactive protein diagnostic tests, immunoglobulin diagnostic tests, and prealbumin diagnostic tests. Among these, the C-reactive protein or CRP diagnostic tests market has attracted significant focus in the past due to the efficacy of the test in diagnosing disorders related to inflammation accurately.
Infectious disease testing, endocrine testing, allergy testing, oncology testing, toxicology testing, and autoimmune disease testing are the various market segments based on the application of immunoprotein diagnostic testing. The oncology testing market is likely to generate the biggest share in the overall revenue the global market for immunoprotein diagnostic testing industry is expected to generate during the period of 2013 to 2019. The market for oncology testing will develop at a CAGR of 6% during the period of the forecast, and reach a value of US$4,943.0 million by the end of the forecast period.
In 2012, the global industry for immunoprotein diagnostic testing was valued at US$11,019.7 million. It is expected the global immunoprotein diagnostic testing market will reach US$15,351.0 million in the end of the forecast period, reporting a CAGR of 5.7% during the period of the forecast.
Abcam PLC, Siemens AG, Enzo Life Sciences, Inc., Randox Laboratories Ltd., Thermo Fisher Scientific, Inc., DiaSorin SPA, Fujirebio Diagnostics, Inc., Roche Holding AG, Omega Diagnostics Group PLC, The Binding Site Group Ltd., and Abbott Laboratories, Inc. are the major players participating in the immunoprotein diagnostic testing market.